当前位置: X-MOL 学术Nat. Commun. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants
Nature Communications ( IF 14.7 ) Pub Date : 2023-05-09 , DOI: 10.1038/s41467-023-38066-8
Hong Lei 1 , Aqu Alu 1 , Jingyun Yang 1 , Xi He 1 , Cai He 1 , Wenyan Ren 1 , Zimin Chen 1 , Weiqi Hong 1 , Li Chen 1 , Xuemei He 1 , Li Yang 1, 2 , Jiong Li 1, 2 , Zhenling Wang 1, 2 , Wei Wang 1, 2 , Yuquan Wei 1, 2 , Shuaiyao Lu 3 , Guangwen Lu 1, 2 , Xiangrong Song 1, 2 , Xiawei Wei 1, 2
Affiliation  

Mucosal immunity plays a significant role in the first-line defense against viruses transmitted and infected through the respiratory system, such as SARS-CoV-2. However, the lack of effective and safe adjuvants currently limits the development of COVID-19 mucosal vaccines. In the current study, we prepare an intranasal vaccine containing cationic crosslinked carbon dots (CCD) and a SARS-CoV-2 antigen, RBD-HR with spontaneous antigen particlization. Intranasal immunization with CCD/RBD-HR induces high levels of antibodies with broad-spectrum neutralization against authentic viruses/pseudoviruses of Omicron-included variants and protects immunized female BALB/c mice from Omicron infection. Despite strong systemic cellular immune response stimulation, the intranasal CCD/RBD-HR vaccine also induces potent mucosal immunity as determined by the generation of tissue-resident T cells in the lungs and airway. Moreover, CCD/RBD-HR not only activates professional antigen-presenting cells (APCs), dendritic cells, but also effectively targets nasal epithelial cells, promotes antigen binding via sialic acid, and surprisingly provokes the antigen-presenting of nasal epithelial cells. We demonstrate that CCD is a promising intranasal vaccine adjuvant for provoking strong mucosal immunity and might be a candidate adjuvant for intranasal vaccine development for many types of infectious diseases, including COVID-19.



中文翻译:

阳离子交联碳点佐剂鼻内疫苗诱导针对 Omicron 包含的 SARS-CoV-2 变体的保护性免疫

粘膜免疫在抵御通过呼吸系统传播和感染的病毒(例如 SARS-CoV-2)的一线防御中发挥着重要作用。然而,目前缺乏有效和安全的佐剂限制了 COVID-19 粘膜疫苗的开发。在当前的研究中,我们准备了一种鼻内疫苗,其中包含阳离子交联碳点 (CCD) 和 SARS-CoV-2 抗原,即具有自发抗原颗粒化的 RBD-HR。使用 CCD/RBD-HR 进行鼻内免疫可诱导产生高水平抗体,具有广谱中和作用,可对抗 Omicron 包含的变体的真实病毒/假病毒,并保护免疫的雌性 BALB/c 小鼠免受 Omicron 感染。尽管有强烈的全身细胞免疫反应刺激,鼻内 CCD/RBD-HR 疫苗还可以诱导强大的粘膜免疫,这取决于肺和气道中组织驻留 T 细胞的产生。此外,CCD/RBD-HR不仅可以激活专职抗原呈递细胞(APC)、树突状细胞,还可以有效靶向鼻上皮细胞,通过唾液酸促进抗原结合,令人惊讶地激发鼻上皮细胞的抗原呈递。我们证明,CCD 是一种很有前途的鼻内疫苗佐剂,可激发强大的粘膜免疫力,并可能成为开发多种传染病(包括 COVID-19)的鼻内疫苗的候选佐剂。但也有效地靶向鼻上皮细胞,通过唾液酸促进抗原结合,并令人惊讶地激发鼻上皮细胞的抗原呈递。我们证明,CCD 是一种很有前途的鼻内疫苗佐剂,可激发强大的粘膜免疫力,并可能成为开发针对多种传染病(包括 COVID-19)的鼻内疫苗的候选佐剂。但也有效地靶向鼻上皮细胞,通过唾液酸促进抗原结合,并令人惊讶地激发鼻上皮细胞的抗原呈递。我们证明,CCD 是一种很有前途的鼻内疫苗佐剂,可激发强大的粘膜免疫力,并可能成为开发多种传染病(包括 COVID-19)的鼻内疫苗的候选佐剂。

更新日期:2023-05-10
down
wechat
bug